Announcements
- Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
- Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
- European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
- Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
- Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
- Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
- Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
- Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
More ▼
Key statistics
As of last trade Scinai Immunotherapeutics Ltd (2F50:MUN) traded at 0.424, 0.95% above its 52-week low of 0.42, set on May 03, 2024.
52-week range
Open | 0.424 |
---|---|
High | 0.424 |
Low | 0.424 |
Bid | 0.398 |
Offer | 0.452 |
Previous close | 0.42 |
Average volume | 0.00 |
---|---|
Shares outstanding | 10.88k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 2.03m USD |
EPS (TTM) | -4.16 USD |
Data delayed at least 15 minutes, as of May 06 2024 07:12 BST.
More ▼